MicroRNA-374a Governs Aggressive Cell Behaviors of Glioma by Targeting Prokineticin 2.

MicroRNA-374a Governs Aggressive Cell Behaviors of Glioma by Targeting Prokineticin 2.
Technol Cancer Res Treat. 2019 Jan 01;18:1533033818821401
Authors: Zhang Y, Zhang R, Sui R, Chen Y, Liang H, Shi J, Piao H
Abstract
MicroRNA-374a has been abnormally expressed in several cancer types; however, its role in glioma remains unclear. Therefore, we aimed to investigate whether microR-374a participated in the progression of glioma. Expression of microR-374a in glioma cell lines and normal cell line was measured by quantitative real-time polymerase chain reaction. Luciferase reporter assay and Western blot were used to detect the targets of microR-374a. In vitro functional experiments were conducted to investigate the biological role of microR-374a. Low expression of microR-374a was found in glioma cell lines. Prokineticin 2 was identified as a direct target of microR-374a in glioma. Investigations on the mechanisms related to glioma progression showed that microR-374a inhibited glioma cell proliferation, cell cycle progression, and cell invasion through targeting Prokineticin 2. Taken together, these results revealed that microR-374a functions as tumor suppressor by targeting Prokineticin 2, suggesting it might be a novel therapeutic target for glioma.
PMID: 30803356 [PubMed - in process]

Source: Technology in Cancer Research and Treatment - January 1, 2019 Category: Cancer & Oncology Authors: Zhang Y, Zhang R, Sui R, Chen Y, Liang H, Shi J, Piao H Tags: Technol Cancer Res Treat Source Type: research